首页> 外文期刊>Neurobiology of disease >Diabetic neuropathic pain development in type 2 diabetic mouse model and the prophylactic and therapeutic effects of coenzyme Q10
【24h】

Diabetic neuropathic pain development in type 2 diabetic mouse model and the prophylactic and therapeutic effects of coenzyme Q10

机译:2型糖尿病小鼠模型中糖尿病性神经性疼痛的发生以及辅酶Q10的预防和治疗作用

获取原文
获取原文并翻译 | 示例
           

摘要

The early onset of type 2 diabetes mellitus (DM), driven by increasing obesity, is associated with peripheral neuropathy. Here, we characterize diabetic neuropathic pain in New Zealand obese diabetic mice (NZO/HILtJ) as a polygenic model of obesity with type 2 diabetes and investigate the role of coenzyme Q10 (CoQ10) in the prevention and treatment of diabetic neuropathic pain. Since the overexpression of mitogen-activated protein kinase (MAPK), nuclear factor-κB proteins (NF-Kb), toll-like receptor 4 (TLR4) and downstream cytokines (such as CCL2, CXCL10) are considered important factors contributing to the development of neuropathic pain, the expression of these factors and the inhibitory effects of CoQ10 were evaluated.NZO/HILtJ mice spontaneously developed type 2 DM and increased body mass with diabetic neuropathic pain. CoQ10 treatment decreased pain hypersensitivity and long-term supplementation prevented the development of diabetic neuropathic pain but did not attenuate diabetes. Spinal cord, blood serum, liver tissue, and dorsal root ganglia (DRG) from diabetic mice demonstrated increased lipid peroxidation, which was decreased by CoQ10 treatment. The percentage of positive neurons of p65 (the activated marker of NF-KB) and MAPK in DRG were significantly higher in DM mice compared to controls. However, CoQ10 treatment significantly decreased p65 and MAPK positive neurons in the DRG of DM mice. RT-PCR demonstrated that elevated levels of mRNA of CCL2, CXCL10 or TLR4 in the spinal cord of DM mice decreased significantly when DM mice were treated with CoQ10. Conclusion: This model may be useful in understanding the mechanisms of neuropathic pain in type 2 DM induced neuropathic pain and may facilitate preclinical testing of therapies. CoQ10 may decrease oxidative stress in the central and peripheral nervous system by acting as an anti-oxidant and free-radical scavenger. These results suggest that CoQ10 might be a reasonable preventative strategy for long-term use and using CoQ10 treatment may be a safe and effective long-term approach in the treatment of diabetic neuropathy.
机译:由肥胖增加引起的2型糖尿病(DM)的早期发作与周围神经病变有关。在这里,我们将新西兰肥胖型糖尿病小鼠(NZO / HILtJ)中的糖尿病性神经性疼痛定性为2型糖尿病肥胖的多基因模型,并研究辅酶Q10(CoQ10)在预防和治疗糖尿病性神经性疼痛中的作用。由于丝裂原活化蛋白激酶(MAPK),核因子-κB蛋白(NF-Kb),toll​​样受体4(TLR4)和下游细胞因子(例如CCL2,CXCL10)的过表达被认为是促成发展的重要因素NZO / HILtJ小鼠自发发展为2型DM,并伴随糖尿病性神经性疼痛增加体重,从而评估了神经性疼痛的发生率和CoQ10的抑制作用。辅酶Q10治疗可减轻疼痛超敏反应,长期补充可预防糖尿病性神经性疼痛的发生,但不能减轻糖尿病。糖尿病小鼠的脊髓,血清,肝组织和背根神经节(DRG)表现出脂质过氧化作用增加,而辅酶Q10处理可降低脂质过氧化作用。与对照组相比,DM小鼠中DRG中p65(NF-KB的活化标记)和MAPK阳性神经元的百分比显着更高。但是,辅酶Q10处理可显着降低DM小鼠DRG中的p65和MAPK阳性神经元。 RT-PCR表明,用辅酶Q10处理后,DM小鼠脊髓中CCL2,CXCL10或TLR4的mRNA升高。结论:该模型可能有助于了解2型DM诱发的神经性疼痛的神经性疼痛的机制,并可能有助于治疗前的临床测试。辅酶Q10可以充当抗氧化剂和自由基清除剂,从而降低中枢神经系统和周围神经系统的氧化应激。这些结果表明,CoQ10可能是长期使用的合理预防策略,而使用CoQ10治疗可能是治疗糖尿病性神经病的一种安全有效的长期方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号